← Back to Search

Antiviral

Arm 3: high dose for COVID-19

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1), day 3, day 10 and day 14

Summary

This trial is testing a new medicine called PF-07817883 to see if it can lower the amount of COVID-19 virus in adults who have symptoms but are not hospitalized. The goal is to help these people recover faster by reducing the virus levels in their bodies.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1), day 3, day 10 and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1), day 3, day 10 and day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5
Secondary study objectives
Change From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14
Number of Participants Meeting Pre-defined Criteria For ECG Abnormalities
Number of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities
+3 more

Side effects data

From 2023 Phase 2 trial • 240 Patients • NCT05799495
3%
Alanine aminotransferase increased
3%
Supraventricular extrasystoles
100%
80%
60%
40%
20%
0%
Study treatment Arm
PF-07817883 300mg
Placebo
PF-07817883 100mg
PF-07817883 600mg

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 3: high doseExperimental Treatment1 Intervention
Group II: Arm 2: medium doseExperimental Treatment1 Intervention
Group III: Arm 1: low doseExperimental Treatment1 Intervention
Group IV: Arm 4: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07817883
2022
Completed Phase 2
~370

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,661 Previous Clinical Trials
17,844,749 Total Patients Enrolled
72 Trials studying COVID-19
4,890,891 Patients Enrolled for COVID-19
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,546 Previous Clinical Trials
14,885,905 Total Patients Enrolled
55 Trials studying COVID-19
4,879,801 Patients Enrolled for COVID-19

Media Library

PF-07817883 (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT05799495 — Phase 2
COVID-19 Research Study Groups: Arm 3: high dose, Arm 4: Placebo, Arm 1: low dose, Arm 2: medium dose
COVID-19 Clinical Trial 2023: PF-07817883 Highlights & Side Effects. Trial Name: NCT05799495 — Phase 2
PF-07817883 (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05799495 — Phase 2
~96 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top